Mitsubishi UFJ Asset Management Co. Ltd. Invests $160.53 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Mitsubishi UFJ Asset Management bought 257,450 Regeneron shares worth approximately $160.5 million in the second quarter, while institutional investors collectively owned 83.31% of the company.
• Analysts maintain a “Moderate Buy” consensus on REGN, with 16 Buy and 10 Hold ratings and an average price target of $801.70; several firms recently lowered their targets.
• Regeneron reported quarterly earnings of $14.29 per share, surpassing estimates by $4.13, while revenue rose 16.7% year over year to $4.29 billion. The company also declared a quarterly dividend of $0.94 per share.

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 257,450 shares of the biopharmaceutical company's stock, valued at approximately $160,530,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.24% of Regeneron Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Orbimed Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $11,358,000. Lockheed Martin Investment Management Co. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $2,702,000. National Pension Service increased its stake in Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock valued at $278,636,000 after buying an additional 82,853 shares during the last quarter. AE Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 36.7% in the 4th quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company's stock valued at $4,226,000 after buying an additional 1,470 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $10,472,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on REGN. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating for the company in a research note on Monday, May 18th. Barclays dropped their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a report on Thursday, April 30th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating for the company in a research report on Monday, May 18th. Truist Financial boosted their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Finally, HSBC decreased their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a research note on Monday, July 6th. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $801.70.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of Regeneron Pharmaceuticals stock opened at $805.93 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business has a fifty day simple moving average of $679.69 and a two-hundred day simple moving average of $714.24. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The company has a market capitalization of $82.98 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.37 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company earned $12.81 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,400 shares of company stock worth $1,090,030. Insiders own 6.97% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source